This brand name is authorized in Austria, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Turkey, United Kingdom, United States
The drug SAXENDA contains one active pharmaceutical ingredient (API):
|
1
Liraglutide
UNII 839I73S42A - LIRAGLUTIDE
|
|
Liraglutide is a GLP-1 analogue with 97% sequence homology to human GLP-1 that binds to and activates the GLP-1 receptor. The GLP-1 receptor is the target for native GLP-1, an endogenous incretin hormone that potentiates glucose-dependent insulin secretion from the pancreatic beta cells. Unlike native GLP-1, liraglutide has a pharmacokinetic and pharmacodynamic profile in humans suitable for once daily administration. |
Below package inserts are available for further reading:
| Title | Information Source | Document Type | |
|---|---|---|---|
| SAXENDA Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| A10BJ02 | Liraglutide | A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BJ Glucagon-like peptide-1 (GLP-1) analogues |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: BR | Câmara de Regulação do Mercado de Medicamentos | Identifier(s): 526616060007907, 526616060008007, 526616060008107 |
| Country: CA | Health Products and Food Branch | Identifier(s): 02437899 |
| Country: EC | Agencia Nacional de Regulación, Control y Vigilancia Sanitaria | Identifier(s): 211-MBE-0821 |
| Country: EE | Ravimiamet | Identifier(s): 1681017, 1681028, 1681039 |
| Country: ES | Centro de información online de medicamentos de la AEMPS | Identifier(s): 115992002, 115992003 |
| Country: FI | Lääkealan turvallisuus- ja kehittämiskeskus | Identifier(s): 513490 |
| Country: FR | Base de données publique des médicaments | Identifier(s): 61756418 |
| Country: GB | Medicines & Healthcare Products Regulatory Agency | Identifier(s): 337479, 383795, 385297 |
| Country: HK | Department of Health Drug Office | Identifier(s): 65010 |
| Country: IL | מִשְׂרַד הַבְּרִיאוּת | Identifier(s): 7758 |
| Country: IT | Agenzia del Farmaco | Identifier(s): 044018012, 044018024, 044018036 |
| Country: LT | Valstybinė vaistų kontrolės tarnyba | Identifier(s): 1076039, 1076040, 1076041 |
| Country: NL | Z-Index G-Standaard, PRK | Identifier(s): 151203 |
| Country: NZ | Medicines and Medical Devices Safety Authority | Identifier(s): 17703 |
| Country: PL | Rejestru Produktów Leczniczych | Identifier(s): 100342594 |
| Country: RO | Agenția Națională a Medicamentului și a Dispozitivelor Medicale | Identifier(s): W67457001, W67457002, W67457003 |
| Country: SG | Health Sciences Authority | Identifier(s): 15338P |
| Country: TR | İlaç ve Tıbbi Cihaz Kurumu | Identifier(s): 8699676950157, 8699676950164, 8699676950171 |
| Country: US | FDA, National Drug Code | Identifier(s): 0169-2800, 50090-4257 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
